ClinicalTrials.gg
Not yet recruitingNCT07239921Updated Nov 28, 2025

Disease Characteristics of R-CAD

An observational study in Coronary Artery Disease, Coronary Artery Disease Progression and Coronary Stenosis, sponsored by Peking Union Medical College Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Peking Union Medical College Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
52
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Coronary Artery Disease by Peking Union Medical College Hospital — 5 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · Peking Union Medical College Hospital.

Started
2025
with 1 other
Observational
5 of 10
4 open now
Registered
10th of 10
by date

Among the 10 studies in Coronary Artery Disease by Peking Union Medical College Hospital, this one is one of 2 that started in 2025, is one of 5 observational ones, and was the 10th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 10 studies in Coronary Artery Disease by Peking Union Medical College Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Coronary Artery Disease by Peking Union Medical College Hospital, or all of them as a file.
02

Study summary

The present case-control study is designed to investigate the disease characteristics of rapidly progressive coronary artery disease (R-CAD) by comparing the demographics, clinical features, lab results, imaging findings, and prior treatment between patients in the case group (approximately 34 patients with R-CAD) and those in the control group (approximately 18 patients with non-rapidly progressive coronary artery disease [NR-CAD]).

Read the detailed description

The majority of coronary artery disease (CAD) is atherosclerotic coronary artery disease (AS-CAD), the pathological basis of which is atherosclerosis. Secondary prevention, including healthy life style and medical treatment, effectively controls the progression of AS-CAD. Coronary revascularization, including percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) are the dominant treatment modalities to restore the patency and/or blood flow of the diseased coronary arteries.

A special type of CAD is identified in the investigators' clinical practice, which progresses rapidly and recurs frequently after PCI or CABG, and responds poorly to intensified secondary prevention for AS-CAD. The investigators name this special type of CAD with rapidly progressive coronary artery disease (R-CAD), which has significantly different clinical features from those of typical AS-CAD. The CAD without the above characteristics is named with non-rapidly progressive coronary artery disease (NR-CAD).

Currently, the disease characteristics of R-CAD remain unknown. It has been identified that a proportion of R-CAD patients demonstrate certain manifestations of inflammation, including positive inflammatory markers, or positive autoantibodies, or established diagnosis of chronic inflammatory diseases, or use of immunosuppressive therapy, whose R-CAD is named as inflammation-associated rapidly progressive coronary artery disease (IR-CAD). However, the rest of R-CAD patients demonstrate no manifestations of inflammation. Therefore, the present case-control study is designed to investigate the disease characteristics of the overall R-CAD patients by comparing the demographics, clinical features, lab results, imaging findings, and prior treatment between the case group (approximately 34 patients with R-CAD) and the control group (approximately 18 patients with NR-CAD).

Patients will be enrolled in the case group (R-CAD patients) of the present case-control study if they 1) have prior history of coronary revascularization (PCI or CABG); 2) received standard treatment for secondary prevention of AS-CAD after the latest coronary revascularization; 3) have evidence of rapidly progressive myocardial ischemia leading to hospitalization and/or coronary revascularization; 4) have angiographic evidence of rapidly progressive coronary lesions leading to myocardial ischemia.

Patients will be enrolled in the control group (NR-CAD patients) of the present case-control study if they 1) are 35 to 75 years old; 2) received standard treatment for secondary prevention of AS-CAD after the latest PCI which was performed 12±6 months ago; 3) do not have evidence of rapidly progressive myocardial ischemia leading to hospitalization and/or coronary revascularization; 4) do not have angiographic evidence of rapidly progressive coronary lesions leading to myocardial ischemia.

Once enrolled, patients in both groups will receive examinations and evaluations according to a clinical management protocol specifically designed for the clinical management of R-CAD patients. The information regarding the baseline characteristics and the results of examinations and evaluations, including demographics, clinical features, lab results, imaging findings, and prior treatment, will be collected and compared between the case group and the control group.

The primary endpoint is the rate of elevated erythrocyte sedimentation rate (ESR) or high-sensitivity C-reactive protein (hs-CRP).

03

Conditions studied

  • Coronary Artery Disease
  • Coronary Artery Disease Progression
  • Coronary Stenosis
  • Coronary Restenosis
  • Coronary Stent Occlusion
  • Myocardial Revascularization
  • Percutaneous Coronary Intervention

Keywords

  • Coronary Artery Disease
  • Coronary Stenosis
  • Coronary Restenosis
  • Myocardial Revascularization
  • Percutaneous Coronary Intervention
  • Disease Progression
  • Disease Attributes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who fulfill the inclusion/exclusion criteria for R-CAD defined by the protocol of the present case-control study will be enrolled in the case group of the present case-control study.

Patients who fulfill the inclusion/exclusion criteria for NR-CAD defined by the protocol of the present case-control study will be enrolled in the control group of the present case-control study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Case Group (R-CAD patients):

  1. 18 years of age or older, male or female.
  2. Negative results of urine or blood pregnancy test for females with (not or surgically sterile).
  3. Prior history of coronary revascularization (PCI or CABG).
  4. Receiving standard treatment for secondary prevention of AS-CAD after the latest coronary revascularization.
  5. Rapidly progressive myocardial ischemia leading to hospitalization and/or coronary revascularization:

    1. Typical symptoms of angina (Canadian Cardiovascular Society [CCS] classification III-IV) and non-invasive evidence of myocardial ischemia; and
    2. Occurred within 6 months of the latest ischemia-driven hospitalization and/or coronary revascularization.
  6. Rapidly progressive coronary lesions leading to myocardial ischemia:

    1. Angiographic evidence of new-onset or worsened coronary de novo or restenotic lesions relevant to myocardial ischemia, and
    2. Occurred within 6 months of the latest ischemia-driven coronary angiography and/or revascularization.

Control Group (NR-CAD patients):

  1. 35 to 75 years old*, male or female. (* Based on the age distribution characteristics of patients who have been diagnosed as R-CAD.)
  2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).
  3. Currently, at 12±6 months after the latest PCI.
  4. Receiving standard treatment for secondary prevention of AS-CAD after the latest PCI.
  5. Coronary angiography and/or optical coherence tomography (OCT) performed during the index hospitalization.
  6. No evidence of rapidly progressive myocardial ischemia and coronary lesions, i.e., not fulfilling items 5) and 6) of the inclusion criteria for R-CAD.

Exclusion criteria

Exclusion Criteria:

  1. Receiving therapy within 6 months.
  2. Coronary restenosis due to mechanical factors (stent under-expansion, stent mal-apposition, stent rupture, et al).
  3. Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).
  4. Active (diagnosed within 12 months or with ongoing requirement for treatment).
  5. Vital organ failure.
  6. \< 1 year.
  7. In pregnancy or breast-feeding, or with intention to be pregnant during the study period.
  8. Risk of non-compliance (history of drug addiction or alcohol abuse, et al).
  9. Previous enrollment in this study.
  10. Participation in another study within 30 days.
  11. Involvement in the planning and conduct of this study (applying to investigators, contract research organization staffs, study site staffs, et al).
  12. Any condition, which in the opinion of the investigators, would make it unsuitable for the patient to participate in this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
52 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Case Group

    R-CAD patients

    Diagnostic Test: Protocol-defined Examinations and Evaluations

  • Control Group

    NR-CAD patients

    Diagnostic Test: Protocol-defined Examinations and Evaluations

Interventions

  • Diagnostic testProtocol-defined Examinations and Evaluations

    Lab tests (blood and urine and stool routine tests, hepatic and renal and thyroid function tests, tests for metabolic markers, tests for cardiac biomarkers, thrombosis-related tests, rheumatology tests, tests for inflammation markers), electrocardiography, echocardiography, 6-minute walk test, vascular ultrasound, coronary angiography, optical coherence tomography (OCT), fibroblast activation protein inhibitor positron emission tomography/computed tomography (FAPI-PET/CT), photon-counting detector coronary computed tomography angiography (PCD-CCTA), tests for exploratory biomarkers.

06

What researchers measure

Primary outcomes

  1. Elevated ESR or hs-CRP

    Percentage of patients with elevated ESR (\> 15 mm/h for male or \> 20 mm/h for female) or hs-CRP (≥ 2 mg/L).

    Time frame: From 30 days before enrollment up to 14 days after enrollment, but before the initiation of immunosuppressive therapy.

Secondary outcomes

  1. Positive autoantibodies

    Percentage of patients with positive autoantibodies (anti-nuclear antibody \[ANA\], anti-neutrophil cytoplasmic antibody \[ANCA\], anti-endothelial cell antibody \[AECA\], lupus anticoagulant \[LA\], antiphospholipid antibody (APL) (anti-cardiolipin antibody \[ACL\], anti-beta2-glycoprotein 1 antibody \[abeta2GP1\]), anti-phosphatidylserine antibody \[APSA\], rheumatoid factor \[RF\], anti-cyclic citrullinated peptide antibody \[anti-CCP\], et al.).

    Time frame: From 30 days before enrollment up to 14 days after enrollment, but before the initiation of immunosuppressive therapy.

  2. Established diagnosis of chronic inflammatory diseases

    Percentage of patients with established diagnosis of chronic inflammatory diseases (chronic infectious disease, autoimmune disease, other chronic inflammatory diseases, et al.).

    Time frame: Up to 14 days after enrollment

  3. Elevated ESR or hs-CRP, or positive autoantibodies

    Percentage of patients with elevated ESR or hs-CRP, or positive autoantibodies.

    Time frame: From 30 days before enrollment up to 14 days after enrollment, but before the initiation of immunosuppressive therapy.

  4. Elevated ESR or hs-CRP, or positive autoantibodies, or established diagnosis of chronic inflammatory diseases

    Percentage of patients with elevated ESR or hs-CRP, or positive autoantibodies, or established diagnosis of chronic inflammatory diseases.

    Time frame: For elevated ESR or hs-CRP and positive autoantibodies: from 30 days before enrollment up to 14 days after enrollment, but before the initiation of immunosuppressive therapy; for established diagnosis of chronic inflammatory diseases: up to 14 days after

Other outcomes

  1. Maximum standardized uptake value (SUVmax)

    SUVmax based on fibroblast activation protein inhibitor positron emission tomography/computed tomography (FAPI-PET/CT).

    Time frame: From 30 days before enrollment up to 14 days after enrollment, but before the initiation of immunosuppressive therapy.

  2. Maximum target background ratio (TBRmax)

    TBRmax based on fibroblast activation protein inhibitor positron emission tomography/computed tomography (FAPI-PET/CT).

    Time frame: From 30 days before enrollment up to 14 days after enrollment, but before the initiation of immunosuppressive therapy.

  3. Fat attenuation index (FAI)

    FAI based on photon-counting detector coronary computed tomography angiography (PCD-CCTA).

    Time frame: From 30 days before enrollment up to 14 days after enrollment, but before the initiation of immunosuppressive therapy.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2025; primary completion for Oct 2026, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Nov 20, 2025
StartEst.
Nov 2025
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07239921
Responsible party
LiuZhenyu (Professor, Peking Union Medical College Hospital) — Principal investigator
First posted
Nov 20, 2025
Start date
Nov 2025 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Nov 28, 2025

Study contacts

Zhenyu Liu, M.D.
Contact
Pumch_lzy@163.com
+861069155068
Lihong Xu, B.N.
Contact
xulihong1990@163.com
+861069155068
Zhenyu Liu, M.D.
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion